Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Read the full article on WikipediaStage IV clear cell variant renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Initial treatment Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) following prior treatment with a tyrosine kinase inhibitor, AND Patient must have a WHO performance status of 2 or less, AND The treatment must be the sole PBS-subsidised therapy for this condition. Patients who have developed intolerance to a tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised treatment with this drug. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.
Advanced Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma Clinical criteria: Treatment Phase: Initial treatment The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have a WHO performance status of 2 or less, AND Patient must have Child Pugh class A, AND The condition must be untreated with systemic therapy; OR Patient must have developed intolerance of a severity necessitating permanent treatment withdrawal, in the absence of disease progression, to any of the following: (i) a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), (ii) atezolizumab/bevacizumab combination therapy, (iii) durvalumab/tremelimumab combination therapy.
“Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. Of the RAF kinases, sorafenib is more selective for c-Raf than B-RAF. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)”
“25–48 hours”
Working under the parallel aged-care framework? Aged-care equivalent →